Advanced search
1 file | 224.13 KB

Fused-core HPLC method development implemented in a short-term stability study of Triple IT solution

Author
Organization
Abstract
For the majority of children with acute lymphoblastic leukemia (ALL), treatment consists in part of a triple intrathecal (Triple IT) therapy, i.e. a combination of cytarabine (CB), methotrexate (MTX) and methylprednisolone sodium succinate (MPSS) [1]. This combination product is prepared ex-tempore. However, no in-use shelf-life under defined storage conditions has yet been established. During stability studies, a large number of samples are generated, thus creating the need for a fast, accurate and selective analytical method. In this study, a fused-core HPLC method was developed. This hybrid technology, consisting of a 0.5 µm thick porous shell fused to a 1.7 µm inert core, enables faster chromatographic separation with sufficiently high resolution. During method development, both stressed and unstressed solutions containing both single Triple IT components and the mixture thereof, were analyzed using different linear gradient times, ranging from 5 to 30 min. The mobile phase composition was fixed (A: 0.1% glacial acid in H2O; B: 0.1% glacial acid in ACN), starting with A:B (90:10, V/V) and ending with A:B (10:90, V/V). Method selectivity was evaluated based on the observed peaks in stressed CB, MTX and MPSS solutions, i.e. incubation at 40°C and 80°C. A balance between fast separation and sufficient resolution between the Triple IT components and related degradants, was found by setting the gradient time at 15 min. The Triple IT related degradation peaks were chromatographically separated from the remaining Triple IT components. Moreover, selectivity was supported by a peak purity analysis on the observed peaks. Linearity was demonstrated (R² > 0.999) for the three Triple IT components. Repeatability was evaluated by triplicate injections of 100% reference assay: relative standard deviation varied between 0.155% (MPSS), 0.464% (CB) and 1.352% (MTX) [2]. References [1] A. Ruggiero, V. Conter, M. Milani, E. Biagi, I. Lazzareschi, P. Sparano, R. Riccardi. Intrathecal chemotherapy with antineoplastic agents in children. Paediatric drugs 3(4) (2001) 237-246. [2] M. D’Hondt, E. Vangheluwe, S. Van Dorpe, J. Boonen, T. Bauters, B. Pelfrene, J. Vandenbroucke, H. Robays, B. De Spiegeleer. Stability of ex-tempore prepared Triple intrathecal solution consisting of cytarabine, methotrexate and methylprednisolone sodium succinate. American Journal of Health-System Pharmacy, submitted for publication.
Keywords
cytarabine, HPLC, methylprednisolone sodium succinate, stability study, methotrexate, method development

Downloads

  • 2011-247b Scientific Afternoon FFW 2011 Matthias.pdf
    • full text
    • |
    • open access
    • |
    • PDF
    • |
    • 224.13 KB

Citation

Please use this url to cite or link to this publication:

Chicago
D’Hondt, Matthias, Elien Vangheluwe, Nadia Lemeire, Tieneke Bauters, BRIGITTE PELFRENE, Johan Vandenbroucke, Hugo Robays, and Bart De Spiegeleer. 2011. “Fused-core HPLC Method Development Implemented in a Short-term Stability Study of Triple IT Solution.” In 3rd Scientific Afternoon, Abstracts.
APA
D’Hondt, Matthias, Vangheluwe, E., Lemeire, N., Bauters, T., PELFRENE, B., Vandenbroucke, J., Robays, H., et al. (2011). Fused-core HPLC method development implemented in a short-term stability study of Triple IT solution. 3rd scientific afternoon, Abstracts. Presented at the 3rd Scientific Afternoon (FFW - 2011).
Vancouver
1.
D’Hondt M, Vangheluwe E, Lemeire N, Bauters T, PELFRENE B, Vandenbroucke J, et al. Fused-core HPLC method development implemented in a short-term stability study of Triple IT solution. 3rd scientific afternoon, Abstracts. 2011.
MLA
D’Hondt, Matthias, Elien Vangheluwe, Nadia Lemeire, et al. “Fused-core HPLC Method Development Implemented in a Short-term Stability Study of Triple IT Solution.” 3rd Scientific Afternoon, Abstracts. 2011. Print.
@inproceedings{1243639,
  abstract     = {For the majority of children with acute lymphoblastic leukemia (ALL), treatment consists in part of a triple intrathecal (Triple IT) therapy, i.e. a combination of cytarabine (CB), methotrexate (MTX) and methylprednisolone sodium succinate (MPSS) [1]. This combination product is prepared ex-tempore. However, no in-use shelf-life under defined storage conditions has yet been established. During stability studies, a large number of samples are generated, thus creating the need for a fast, accurate and selective analytical method. In this study, a fused-core HPLC method was developed. This hybrid technology, consisting of a 0.5 {\textmu}m thick porous shell fused to a 1.7 {\textmu}m inert core, enables faster chromatographic separation with sufficiently high resolution. During method development, both stressed and unstressed solutions containing both single Triple IT components and the mixture thereof, were analyzed using different linear gradient times, ranging from 5 to 30 min. The mobile phase composition was fixed (A: 0.1\% glacial acid in H2O; B: 0.1\% glacial acid in ACN), starting with A:B (90:10, V/V) and ending with A:B (10:90, V/V). Method selectivity was evaluated based on the observed peaks in stressed CB, MTX and MPSS solutions, i.e. incubation at 40{\textdegree}C and 80{\textdegree}C. A balance between fast separation and sufficient resolution between the Triple IT components and related degradants, was found by setting the gradient time at 15 min. The Triple IT related degradation peaks were chromatographically separated from the remaining Triple IT components. Moreover, selectivity was supported by a peak purity analysis on the observed peaks. Linearity was demonstrated (R{\texttwosuperior} {\textrangle} 0.999) for the three Triple IT components. Repeatability was evaluated by triplicate injections of 100\% reference assay: relative standard deviation varied between 0.155\% (MPSS), 0.464\% (CB) and 1.352\% (MTX) [2]. References [1]\unmatched{0009}A. Ruggiero, V. Conter, M. Milani, E. Biagi, I. Lazzareschi, P. Sparano, R. Riccardi. Intrathecal chemotherapy with antineoplastic agents in children. Paediatric drugs 3(4) (2001) 237-246. [2]\unmatched{0009}M. D{\textquoteright}Hondt, E. Vangheluwe, S. Van Dorpe, J. Boonen, T. Bauters, B. Pelfrene, J. Vandenbroucke, H. Robays, B. De Spiegeleer. Stability of ex-tempore prepared Triple intrathecal solution consisting of cytarabine, methotrexate and methylprednisolone sodium succinate. American Journal of Health-System Pharmacy, submitted for publication.},
  author       = {D'Hondt, Matthias and Vangheluwe, Elien and Lemeire, Nadia and Bauters, Tieneke and PELFRENE, BRIGITTE and Vandenbroucke, Johan and Robays, Hugo and De Spiegeleer, Bart},
  booktitle    = {3rd scientific afternoon, Abstracts},
  keyword      = {cytarabine,HPLC,methylprednisolone sodium succinate,stability study,methotrexate,method development},
  language     = {eng},
  location     = {Ghent, Belgium},
  title        = {Fused-core HPLC method development implemented in a short-term stability study of Triple IT solution},
  year         = {2011},
}